Pub. Date : 2005 Oct 28
PMID : 16255777
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 2 | Melanoma cells containing the B-Raf mutation V599E were more sensitive than cells with wild-type B-raf to 10 nM doses of both BAY43-9006 and rapamycin. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 3 | Melanoma cells containing the B-Raf mutation V599E were more sensitive than cells with wild-type B-raf to 10 nM doses of both BAY43-9006 and rapamycin. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 4 | As expected, rapamycin inhibited the phosphorylation of mTOR substrates, p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf activity. | Sorafenib | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |